
PF-1355
CAS No. 1435467-38-1
PF-1355( PF-06281355 | PF 06281355 | ZINC205721785 )
Catalog No. M28021 CAS No. 1435467-38-1
PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 40 | Get Quote |
![]() ![]() |
5MG | 65 | Get Quote |
![]() ![]() |
10MG | 110 | Get Quote |
![]() ![]() |
25MG | 178 | Get Quote |
![]() ![]() |
50MG | 335 | Get Quote |
![]() ![]() |
100MG | 483 | Get Quote |
![]() ![]() |
200MG | 691 | Get Quote |
![]() ![]() |
500MG | 1035 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePF-1355
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.
-
DescriptionPF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.(In Vitro):PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM) .(In Vivo):Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment .
-
In VitroIn a dose-responsive fashion, PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM).
-
In VivoOral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Good pasture disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment.
-
SynonymsPF-06281355 | PF 06281355 | ZINC205721785
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntifungal
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1435467-38-1
-
Formula Weight321.35
-
Molecular FormulaC14H15N3O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (155.59 mM)
-
SMILESO=C1C=C(C=2C=C(OC)C=CC2OC)N(C(=S)N1)CC(=O)N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Prats E, et al. Antifungal activity of a new phenolic compound from capitulum of a head rot-resistant sunflower genotype. J Chem Ecol.?2007 Dec;33(12):2245-53. Epub 2007 Nov 22.
molnova catalog



related products
-
Corymboside
Corymboside is a natural product for research related to life sciences.
-
5-alpha-Hydroxy-Laxo...
5-alpha-Hydroxy-Laxogenin is an stress hormone cortisol inhibitor.
-
ETHYL 2-AMINO-4-METH...
ETHYL 2-AMINO-4-METHYL-5-PHENYLTHIOPHENE-3-CARBOXYLATE targets the prostaglandin E2 receptor EP2 subtype (human).